FDA批準復發(fā)性或難治性急性髓性白血病靶向治療藥物恩西地平上市
發(fā)布時間：2019-03-31 10:42
【摘要】：正2017年8月1日,美國食品和藥物管理局(FDA)批準恩西地平(enasidenib,商品名:Idhifa)用于成年的因特定遺傳基因突變產(chǎn)生的復發(fā)性或難治性急性髓性白血病(acute myeloid leukemia,AML)的治療。FDA同時批準檢測試劑盒Real Time IDH2上市,該檢測試劑盒用于檢測AML患者是否存在IDH2特異性基因突變。恩西地平與Real Time IDH2檢測試劑盒共同使用。恩西地平由Celgene公司生產(chǎn)。Real Time IDH2
[Abstract]:On August 1, 2017, the U.S. Food and Drug Administration (FDA) approved Ensidipine (enasidenib, trade name: Idhifa) for adult recurrent or refractory acute myeloid leukemia (acute myeloid leukemia,) due to specific genetic mutations AML) treatment. The FDA also approved the availability of the test kit Real Time IDH2, which is used to detect IDH2-specific gene mutations in patients with AML. Encedipine is used in conjunction with the Real Time IDH2 detection kit. Ensidipine is produced by Celgene Inc. Real Time IDH2
【分類號】：R979.1
本文編號：2450831
[Abstract]:On August 1, 2017, the U.S. Food and Drug Administration (FDA) approved Ensidipine (enasidenib, trade name: Idhifa) for adult recurrent or refractory acute myeloid leukemia (acute myeloid leukemia,) due to specific genetic mutations AML) treatment. The FDA also approved the availability of the test kit Real Time IDH2, which is used to detect IDH2-specific gene mutations in patients with AML. Encedipine is used in conjunction with the Real Time IDH2 detection kit. Ensidipine is produced by Celgene Inc. Real Time IDH2
【分類號】：R979.1
【相似文獻】
相關(guān)期刊論文 前2條
1 欒雪梅;;新藥公告欄[J];中國處方藥;2008年07期
2 王曉艷;鐘磊;付曉玉;楊慧雯;李琳麗;;HPLC測定降解過程中新型靶向藥物SKLB-1103的含量[J];華西藥學雜志;2012年06期
，本文編號：2450831
本文鏈接：http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2450831.html
最近更新
教材專著
